Skip to content
OpenCapital
Get started

Inhibrx Biosciences, Inc. INBX Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Rogers Corporation logo
Rogers CorporationROG
$195.8M+11.5%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
Nuvation Bio logo
Nuvation BioNUVB
$125.39M+161%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$62.1M+24.5%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+385%
Enterprise value$1.42B+982%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s cash & equivalents?
Inhibrx Biosciences, Inc. (INBX) reported cash & equivalents of $161.66M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s cash & equivalents changed year-over-year?
Inhibrx Biosciences, Inc.'s cash & equivalents decreased by 25.3% year-over-year, from $216.52M to $161.66M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s cash & equivalents?
Over 3 years (2022 to 2025), Inhibrx Biosciences, Inc.'s cash & equivalents has grown at a -23.2% compound annual growth rate (CAGR), from $273.87M to $124.22M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.